Chronic Idiopathic Urticaria (CIU) Treatment Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Chronic Idiopathic Urticaria (CIU) Treatment Market is segmented By Route of Administration (Subcutaneous, Intravenous, Oral), By Molecule Type (Monoc....
Competitive overview of Chronic Idiopathic Urticaria (CIU) Treatment Market
The major players operating in the Chronic Idiopathic Urticaria (CIU) Treatment Market include Taizhou Mabtech Pharmaceutical Co. Ltd., Celldex Therapeutics, Allakos, Novartis, GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi, AstraZeneca, UCB Pharma, and Teva Pharmaceuticals.
Chronic Idiopathic Urticaria (CIU) Treatment Market Leaders
- Taizhou Mabtech Pharmaceutical Co. Ltd.
- Celldex Therapeutics
- Allakos
- Novartis
- GlaxoSmithKline
*Disclaimer: Major players are listed in no particular order.
Chronic Idiopathic Urticaria (CIU) Treatment Market - Competitive Rivalry, undefined
Chronic Idiopathic Urticaria (CIU) Treatment Market
Market Consolidated
(Dominated by major players)
(Dominated by major players)
Market Fragmented
(Highly competitive with lots of players.)
(Highly competitive with lots of players.)
*Source: Coherent Market Insights